Preclinical evaluation of [18F]PK-209, a new PET ligand for imaging the ion-channel site of NMDA receptors

Nuclear Medicine and Biology

Volumn 42, Issue 2, 2015, Pages 205-212

  Golla, Sandeep S V ^a   Klein, Pieter J ^a   Bakker, Jaco ^b   Schuit, Robert C ^a   Christiaans, Johannes A M ^a   van Geest, Leo ^b   Kooijman, Esther J M ^a   Oropeza Seguias, Gisela M ^a   Langermans, Jan A M ^b   Leysen, Josée E ^a   Boellaard, Ronald ^a   Windhorst, Albert D ^a   van Berckel, Bart N M ^a   Metaxas, Athanasios ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b BIOMEDICAL PRIMATE RESEARCH CENTRE   (Netherlands)

Author keywords

Brain; Imaging; Ion channel; NMDA; PET; 18F PK 209

Indexed keywords

3 [2 CHLORO 5 (METHYLTHIO)PHENYL] 1 [3 (FLUOROMETHOXY)PHENYL] 1 METHYLGUANIDINE F 18; DIZOCILPINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; 3-(2-CHLORO-5-(METHYLTHIO)PHENYL)-1-(3-(FLUOROMETHOXY)PHENYL)-1-METHYLGUANIDINE; DIZOCILPINE MALEATE; FLUORINE; GUANIDINE; GUANIDINE DERIVATIVE; LIGAND;

ADULT; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; BRAIN CORTEX; CEREBELLUM; CONTROLLED STUDY; CORPUS STRIATUM; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG METABOLISM; DRUG RETENTION; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; FRONTAL LOBE; IN VITRO STUDY; MALE; NONHUMAN; OCCIPITAL LOBE; PET SCANNER; POSITRON EMISSION TOMOGRAPHY; RADIOACTIVITY; RHESUS MONKEY; TEMPORAL LOBE; ANIMAL; BRAIN; DIAGNOSTIC USE; DRUG EFFECTS; METABOLISM; PROCEDURES; SCINTISCANNING;

ANIMALS; BRAIN; DIZOCILPINE MALEATE; FLUORINE RADIOISOTOPES; GUANIDINE; GUANIDINES; LIGANDS; MACACA MULATTA; MALE; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 84921286032     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2014.09.006     Document Type: Article

References (41)

1. Paoletti P., Bellone C., Zhou Q. NMDA receptor subunit diversity: impact on receptor properties, synaptic plasticity and disease. Nat Rev Neurosci 2013, 14:383-400.
2. Olney J.W. Excitotoxicity, apoptosis and neuropsychiatric disorders. Curr Opin Pharmacol 2003, 3:101-109.
3. Parsons M.P., Raymond L.A. Extrasynaptic NMDA receptor involvement in central nervous system disorders. Neuron 2014, 82:279-293.
4. Tarabeux J., Kebir O., Gauthier J., Hamdan F.F., Xiong L., Piton A., et al. Rare mutations in N-methyl-D-aspartate glutamate receptors in autism spectrum disorders and schizophrenia. Transl Psychiatry 2011, 1:e55.
5. Madsen H.B., Brown R.M., Lawrence A.J. Neuroplasticity in addiction: cellular and transcriptional perspectives. Front Mol Neurosci 2012, 5:99.
6. Gonda X. Basic pharmacology of NMDA receptors. Curr Pharm Des 2012, 18:1558-1567.
7. Javitt D.C., Zukin S.R. Biexponential kinetics of [3H]MK-801 binding: evidence for access to closed and open N-methyl-D-aspartate receptor channels. Mol Pharmacol 1989, 35:387-393.
8. Waterhouse R.N. Imaging the PCP site of the NMDA ion channel. Nucl Med Biol 2003, 30:869-878.
9. Sobrio F., Gilbert G., Perrio C., Barre L., Debruyne D. PET and SPECT imaging of the NMDA receptor system: an overview of radiotracer development. Mini Rev Med Chem 2010, 10:870-886.
10. Sobrio F. Radiosynthesis of carbon-11 and fluorine-18 labelled radiotracers to image the ionotropic and metabotropic glutamate receptors. J Labelled Comp Radiopharm 2013, 56:180-186.
11. Klein P.J., Christiaans J.A.M., Metaxas A., Schuit R.C., Lammertsma A.A., van Berckel B.N.M., et al. Synthesis, structure activity relationship, radiolabelling and preclinical evaluation of high affinity ligands for the ion channel of the N-Methyl-D-aspartate receptor as potential imaging probes for positron emission tomography 2014, [Submitted for publication]. 10.1016/j.bmc.2014.12.029.
12. Klein P.J., Christiaans J.A.M., Metaxas A., Lammertsma A.A., van Berckel B.N.M., Windhorst A.D. Novel radiotracer development poster abstracts. J Cereb Blood Flow Metab 2012, 32:S100-S127.
13. Klein PJ, Metaxas A, Windhorst AD, Christiaans JAM, van Berckel BNM. N, n-substituted guanidine compound. Patent 2012; WO2012165956A1.
14. Bakker J., Thuesen L.R., Braskamp G., Skaanild M.T., Ouwerling B., Langermans J.A., et al. Single subcutaneous dosing of cefovecin in rhesus monkeys (Macaca mulatta): a pharmacokinetic study. J Vet Pharmacol Ther 2011, 34:464-468.
15. Tsukada H., Nishiyama S., Fukumoto D., Sato K., Kakiuchi T., Domino E.F. Chronic NMDA antagonism impairs working memory, decreases extracellular dopamine, and increases D1 receptor binding in prefrontal cortex of conscious monkeys. Neuropsychopharmacology 2005, 30:1861-1869.
16. de Jong H.W., van Velden F.H., Kloet R.W., Buijs F.L., Boellaard R., Lammertsma A.A. Performance evaluation of the ECAT HRRT: an LSO-LYSO double layer high resolution, high sensitivity scanner. Phys Med Biol 2007, 52:1505-1526.
17. Cizek J., Herholz K., Vollmar S., Schrader R., Klein J., Heiss W.D. Fast and robust registration of PET and MR images of human brain. NeuroImage 2004, 22:434-442.
18. Rohlfing T., Kroenke C.D., Sullivan E.V., Dubach M.F., Bowden D.M., Grant K.A., et al. The INIA19 template and NeuroMaps atlas for primate brain image parcellation and spatial normalization. Front Neuroinform 2012, 6:27.
19. Logan J. Graphical analysis of PET data applied to reversible and irreversible tracers. Nucl Med Biol 2000, 27:661-670.
20. Waterhouse R.N., Slifstein M., Dumont F., Zhao J., Chang R.C., Sudo Y., et al. In vivo evaluation of [11C]N-(2-chloro-5-thiomethylphenyl)-N'-(3-methoxy-phenyl)-N'-methylguanid ine ([11C]GMOM) as a potential PET radiotracer for the PCP/NMDA receptor. Nucl Med Biol 2004, 31:939-948.
21. Wong E.H., Kemp J.A., Priestley T., Knight A.R., Woodruff G.N., Iversen L.L. The anticonvulsant MK-801 is a potent N-methyl-D-aspartate antagonist. Proc Natl Acad Sci U S A 1986, 83:7104-7108.
22. Blin J., Denis A., Yamaguchi T., Crouzel C., MacKenzie E.T., Baron J.C. PET studies of [18F]methyl-MK-801, a potential NMDA receptor complex radioligand. Neurosci Lett 1991, 121:183-186.
23. Ouyang X., Mukherjee J., Yang Z.Y. Synthesis, radiosynthesis, and biological evaluation of fluorinated thienylcyclohexyl piperidine derivatives as potential radiotracers for the NMDA receptor-linked calcium ionophore. Nucl Med Biol 1996, 23:315-324.
24. Samnick S., Ametamey S., Leenders K.L., Vontobel P., Quack G., Parsons C.G., et al. Electrophysiological study, biodistribution in mice, and preliminary PET evaluation in a rhesus monkey of 1-amino-3-[18F]fluoromethyl-5-methyl-adamantane (18F-MEM): a potential radioligand for mapping the NMDA-receptor complex. Nucl Med Biol 1998, 25:323-330.
25. Shiue C.Y., Vallabhahosula S., Wolf A.P., Dewey S.L., Fowler J.S., Schlyer D.J., et al. Carbon-11 labelled ketamine-synthesis, distribution in mice and PET studies in baboons. Nucl Med Biol 1997, 24:145-150.
26. Bowery N.G., Wong E.H., Hudson A.L. Quantitative autoradiography of [3H]-MK-801 binding sites in mammalian brain. Br J Pharmacol 1988, 93:944-954.
27. Hartvig P., Valtysson J., Antoni G., Westerberg G., Langstrom B., Ratti Moberg E., et al. Brain kinetics of (R)- and (S)-[N-methyl-11C]ketamine in the rhesus monkey studied by positron emission tomography (PET). Nucl Med Biol 1994, 21:927-934.
28. McGinnity C.J., Hammers A., Riano Barros D.A., Luthra S.K., Jones P.A., Trigg W., et al. Initial evaluation of 18F-GE-179, a putative PET tracer for activated N-methyl D-aspartate receptors. J Nucl Med 2014, 55:423-430.
29. Sakurai S.Y., Cha J.H., Penney J.B., Young A.B. Regional distribution and properties of [3H]MK-801 binding sites determined by quantitative autoradiography in rat brain. Neuroscience 1991, 40:533-543.
30. Tacconi S., Ratti E., Marien M.R., Gaviraghi G., Bowery N.G. Inhibition of [3H]-(+)-MK 801 binding to rat brain sections by CPP and 7-chlorokynurenic acid: an autoradiographic analysis. Br J Pharmacol 1993, 108:577-582.
31. Borschel W.F., Myers J.M., Kasperek E.M., Smith T.P., Graziane N.M., Nowak L.M., et al. Gating reaction mechanism of neuronal NMDA receptors. J Neurophysiol 2012, 108:3105-3115.
32. Quarum M.L., Parker J.D., Keana J.F., Weber E. (+)-[3H]MK-801 binding sites in postmortem human brain. J Neurochem 1990, 54:1163-1168.
33. Haradahira T., Okauchi T., Maeda J., Zhang M.R., Kida T., Kawabe K., et al. A positron-emitter labeled glycine(B) site antagonist, [(11)C]L-703,717, preferentially binds to a cerebellar NMDA receptor subtype consisting of GluR epsilon3 subunit in vivo, but not in vitro. Synapse 2002, 43:131-133.
34. Erlandsson K., Bressan R.A., Mulligan R.S., Gunn R.N., Cunningham V.J., Owens J., et al. Kinetic modelling of [123I]CNS 1261-a potential SPET tracer for the NMDA receptor. Nucl Med Biol 2003, 30:441-454.
35. Roussel S., Pinard E., Seylaz J. The acute effects of MK-801 on cerebral blood flow and tissue partial pressures of oxygen and carbon dioxide in conscious and alpha-chloralose anaesthetized rats. Neuroscience 1992, 47:959-965.
36. Garzon J., Rodriguez-Munoz M., Sanchez-Blazquez P. Direct association of Mu-opioid and NMDA glutamate receptors supports their cross-regulation: molecular implications for opioid tolerance. Curr Drug Abuse Rev 2012, 5:199-226.
37. Rodriguez-Munoz M., Sanchez-Blazquez P., Vicente-Sanchez A., Berrocoso E., Garzon J. The mu-opioid receptor and the NMDA receptor associate in PAG neurons: implications in pain control. Neuropsychopharmacology 2012, 37:338-349.
38. Oh S., Kim J.I., Chung M.W., Ho I.K. Modulation of NMDA receptor subunit mRNA in butorphanol-tolerant and -withdrawing rats. Neurochem Res 2000, 25:1603-1611.
39. Miyamoto Y., Yamada K., Nagai T., Mori H., Mishina M., Furukawa H., et al. Behavioural adaptations to addictive drugs in mice lacking the NMDA receptor epsilon1 subunit. Eur J Neurosci 2004, 19:151-158.
40. Christiaans J.A.M., Klein P.J., Metaxas A., Kooijman E.J.M., Schuit R.C., Leysen J.E., et al. Synthesis and preclinical evaluation of carbon-11 labelled N-((5-(4-fluoro-2-[11C]methoxyphenyl)pyridin-3-yl)methyl)cyclopentanamine as a PET tracer for NR2B subunit-containing NMDA receptors. Nucl Med Biol 2014, [epub ahead of print 10 May 2014]. 10.1016/j.nucmedbio.2014.04.131.
41. Murray F., Kennedy J., Hutson P.H., Elliot J., Huscroft I., Mohnen K., et al. Modulation of [3H]MK-801 binding to NMDA receptors in vivo and in vitro. Eur J Pharmacol 2000, 397:263-270.